Lenvima sales are up solidly by around 10%, with Leqembi launching into its commercial phase now at 29.4 billion JPY cumulatively. Sequential performance has been solid. With a 42.5 billion JPY ...

Merck, Eisai's star-crossed Keytruda-Lenvima combo misses survival goal ... by the company’s Biogen-partnered Alzheimer’s med Leqembi (lecanemab), which was heralded as a major breakthrough ...

The cost of Lenvima can vary based on several factors, including your insurance coverage. Coupons and drug savings programs can also lower the price you’ll pay for Lenvima. As with all ...

New York, USA, March 03, 2025 (GLOBE NEWSWIRE) -- LEQEMBI Market Sales Reflect Growing Confidence in Disease-Modifying Alzheimer’s Treatments| DelveInsight LEQEMBI (lecanemab) has significant ...

Days after suffering a rejection in Australia, the Alzheimer’s drug hit another roadblock in the U.K., which found the drug ...

This is the second time NICE made a decision not to approve these treatments for NHS use. Leqembi, marketed by Biogen and Eisai, was first rejected for NHS coverage in August 2024, while a ...

Leqembi’s application now moves forward to the European Commission, which will issue a formal verdict for the injection that ...

New York, USA, March 03, 2025 (GLOBE NEWSWIRE) -- LEQEMBI Market Sales Reflect Growing Confidence in Disease-Modifying Alzheimer’s Treatments| DelveInsight LEQEMBI (lecanemab) has significant market ...

For patients with unresectable, non-metastatic hepatocellular carcinoma, Lenvima plus Keytruda in combination with TACE improved outcomes. Among patients with unresectable, non-metastatic ...

In August, NICE declined to recommend Biogen and Eisai’s Leqembi (lecanemab) for reimbursement. Three months later, NICE followed with the same decision on Lilly’s Kisunla (donanemab).

Lenvima/Welireg combination showed the highest ORR (46.9%) and CBR (59%) among treatment arms in advanced ccRCC patients. Median progression-free survival was longest in the Lenvima/Welireg arm at ...

Biogen and Eisai said the European Medicines Agency's Committee for Medicinal Products for Human Use has reaffirmed its recommended approval of their Alzheimer's drug Leqembi. The companies on Friday ...